Mirdametinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 1 mg, 2mg
Reference Brands: Gomekli (USA), Ezmekly (EU/UK)
Category:
Oncology Cancer Care
Mirdametinib is an orally administered small-molecule inhibitor of MEK1 and MEK2 (part of the RAS/RAF/MEK/ERK signalling pathway).
It is indicated for the treatment of patients (2 years and older) with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely removed by surgery.
Mirdametinib is available in Capsules
and strengths such as 1 mg, 2mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Mirdametinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Mirdametinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing